Core Insights - The conference call is focused on the interim clinical data from the MyPEAK-1 Phase Ib/IIa trial of TN-201 for MYBPC3-associated hypertrophic cardiomyopathy (HCM) [2] - The data was presented at the American Heart Association's scientific sessions, highlighting advancements in HCM care [2] Company Overview - Tenaya Therapeutics is led by CEO Faraz Ali and Chief Medical Officer Dr. Whit Tingley, who are participating in the conference call to discuss the clinical trial data [3]